These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26603536)

  • 1. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.
    Caron PJ; Bevan JS; Petersenn S; Houchard A; Sert C; Webb SM;
    Pituitary; 2016 Apr; 19(2):149-57. PubMed ID: 26603536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.
    Bolanowski M; Hubalewska-Dydejczyk A; Kos-Kudła B; Ruchała M; Witek P; Zgliczyński W; Houchard A; Bartmańska M
    Endokrynol Pol; 2021; 72(5):512-519. PubMed ID: 34647602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
    Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
    Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
    BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.
    Lombardi G; Minuto F; Tamburrano G; Ambrosio MR; Arnaldi G; Arosio M; Chiarini V; Cozzi R; Grottoli S; Mantero F; Bogazzi F; Terzolo M; Tita P; Boscani PF; Colao A
    J Endocrinol Invest; 2009 Mar; 32(3):202-9. PubMed ID: 19542735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
    Caron PJ; Bevan JS; Petersenn S; Flanagan D; Tabarin A; Prévost G; Maisonobe P; Clermont A;
    J Clin Endocrinol Metab; 2014 Apr; 99(4):1282-90. PubMed ID: 24423301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
    Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
    Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
    Petersenn S; Houchard A; Sert C; Caron PJ;
    Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
    Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
    Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLINICAL OUTCOMES AND SELF-REPORTED SYMPTOMS IN PATIENTS WITH ACROMEGALY: AN 8-YEAR FOLLOW-UP OF A LANREOTIDE STUDY.
    Khairi S; Sagvand BT; Pulaski-Liebert KJ; Tritos NA; Klibanski A; Nachtigall LB
    Endocr Pract; 2017 Jan; 23(1):56-65. PubMed ID: 27682353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
    Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
    Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.